Forget COVID: Moderna Is Turning Into a Cancer Company -- and Wall Street Is Taking Notice

MRNA trades 61% above Wall Street's average price target of $123, even after a rally exceeding 600% this year. That gap is the central tension for traders: the stock has priced in a pivot far beyond what analysts currently model.

The driver is oncology. Moderna announced positive phase 3 results for its personalized cancer vaccine, intismeran autogene, paired with MRK's Keytruda in melanoma. The data gives MRNA a late-stage proof point for a business beyond COVID-19 vaccines, where the company built its identity.

The market opportunity framing is large. The global oncology market is projected to grow from $253 billion to more than $700 billion by 2034. That projection supports the bull case for a successful cancer franchise, though it does not guarantee any share for MRNA.

Interpretation: a 61% premium to the consensus target means the stock's price reflects expectations that analysts have not yet adopted. Either targets move sharply higher, or the shares are vulnerable to a reset. The partnership with MRK, whose Keytruda anchors the combination regimen, adds a large-cap partner to the story. PFE appears in this setup only as a peer in the large-cap pharma group.